Oridonin Handling & Assay Protocol | Research Use

Oridonin is a bioactive ent-kaurane diterpenoid isolated from Rabdosia rubescens that is widely used in research as a tool compound for studying apoptosis, cell-cycle arrest, and anti-inflammatory signaling pathways.

CAS Number

28957-04-2

Molecular Formula

C₂₀H₂₈O₆

Molecular Weight

364.43 g/mol

Recommended Storage

-20 °C, protected from light and moisture

Solubility (DMSO)

Soluble; prepare a ≥10 mM stock in DMSO as starting point (verify empirically)

SKU

O111381

Materials and Reagents Required

Before beginning, ensure the following materials are available:

• Oridonin (Aladdin Scientific, SKU O111381) — store at −20 °C until use
• Anhydrous DMSO (cell-culture grade, ≥99.9 % purity)
• Phosphate-buffered saline (PBS, sterile, pH 7.4)
• Complete cell-culture medium appropriate for your cell line
• 0.22 µm syringe filters (if aqueous dilutions require sterile filtration)
• Microcentrifuge tubes (1.5 mL, low-protein-binding recommended)
• Analytical balance and calibrated micropipettes
• Personal protective equipment: nitrile gloves, lab coat, and safety glasses

Note: All solutions containing DMSO must not be passed through standard cellulose acetate filters; use PVDF or PTFE membranes.

Stock Solution Preparation

Follow these steps to prepare a stock solution of Oridonin:

1. Equilibrate to room temperature: Remove the vial from −20 °C storage and allow it to warm to room temperature (approximately 15–20 min) before opening, to prevent condensation from contacting the powder.
2. Calculate the required volume: Use the formula V (mL) = mass (mg) ÷ [MW (g/mol) × target concentration (mM) × 10⁻³]. For a 10 mM stock from 5 mg of Oridonin (MW = 364.43 g/mol): V = 5 ÷ (364.43 × 10 × 10⁻³) ≈ 1.37 mL DMSO.
3. Dissolve: Add the calculated volume of anhydrous DMSO directly to the vial or transfer the powder to a low-binding microcentrifuge tube and add solvent. Vortex for 30–60 seconds, then briefly sonicate (30 s in a bath sonicator) if particulates remain.
4. Verify clarity: Inspect the solution visually; it should be clear and colourless to pale yellow. Do not proceed with a turbid stock.
5. Aliquot and store: Dispense into single-use aliquots to avoid freeze–thaw cycles. Seal under inert gas (argon or nitrogen) if long-term stability is required. Store at −20 °C; use within 6 months. Avoid repeated freeze–thaw cycles (limit to ≤3).

Review flag: Specific solubility values (mg/mL or mM) should be confirmed against the Certificate of Analysis for lot O111381 and empirical testing in your laboratory.

Working Solution Preparation and Cell Treatment

Preparing working concentrations from the DMSO stock requires careful dilution to maintain solubility and minimize DMSO cytotoxicity:

1. Pre-warm media: Warm complete culture medium to 37 °C before use.
2. Intermediate dilution (optional): For very low final concentrations, prepare an intermediate aqueous dilution by adding stock dropwise into warm PBS or serum-free medium with continuous gentle vortexing to reduce precipitation risk.
3. Final dilution: Add the required volume of stock (or intermediate) solution to complete medium to achieve the desired final concentration. The final DMSO concentration in culture should not exceed 0.1 % (v/v) to avoid solvent-related cytotoxicity. Always include a vehicle control (equivalent DMSO concentration, no compound).
4. Typical concentration range: Published literature on Oridonin in cell-based studies commonly employs concentrations in the low-to-mid micromolar range; however, the appropriate range is cell-line and endpoint dependent and must be determined empirically with dose–response experiments.
5. Apply to cells: Remove existing medium, add pre-warmed working solution, and incubate for the desired time period at 37 °C in a humidified 5 % CO₂ atmosphere. Include appropriate positive and negative controls.

Review flag: Specific IC₅₀ values for particular cell lines are not cited here; researchers should perform independent dose–response experiments and consult primary literature for their specific model.

Downstream Assay Guidance

Oridonin has been investigated in numerous cellular and molecular assays. The following guidance applies generally:

Cell Viability / Cytotoxicity

MTT, CCK-8, or CellTiter-Glo® luminescent assays are compatible with Oridonin treatments. Prepare a minimum of six concentration points plus vehicle control to generate a full dose–response curve. Assay at 24 h, 48 h, and 72 h to capture time-dependent effects.

Apoptosis Detection

Flow cytometric Annexin V/PI double staining is commonly used to quantify early and late apoptosis following Oridonin treatment. Collect both floating and adherent cells to avoid underestimating apoptotic population. Western blotting for cleaved caspase-3, caspase-9, and PARP can corroborate flow data.

Western Blotting

Lyse cells in RIPA or modified lysis buffer supplemented with protease and phosphatase inhibitors. Typical protein loading: 20–40 µg per lane. Targets reported in Oridonin studies include NF-κB pathway components, Bcl-2 family proteins, and MAPK cascade members — confirm antibody selection with your specific research question.

Controls and Replication

All experiments should include: (1) untreated cells, (2) vehicle (DMSO) control, (3) a positive-control compound where applicable, and (4) biological replicates (n ≥ 3).

Safety, Waste Disposal, and Troubleshooting

Safety: Oridonin is a research reagent intended for laboratory use only. Handle with nitrile gloves, lab coat, and eye protection. Avoid inhalation of dust. Refer to the Safety Data Sheet (SDS) for Oridonin O111381 before use.

Waste Disposal: Dispose of Oridonin-containing solutions and contaminated materials according to your institution's chemical waste regulations. DMSO solutions readily penetrate skin and can carry dissolved compounds; exercise particular care.

Troubleshooting:

Problem	Likely Cause	Suggested Action
Precipitate in working solution	Aqueous solubility limit exceeded or temperature too low	Reduce compound concentration; pre-warm medium; use co-solvent such as PEG-400 if compatible with assay
No biological effect observed	Concentration too low; compound degraded; resistant cell line	Re-check stock concentration; verify compound integrity by HPLC; increase dose; confirm cell-line sensitivity
High DMSO cytotoxicity in vehicle control	DMSO concentration >0.1 %	Prepare more concentrated stock to reduce DMSO volume needed
Inconsistent results across replicates	Inadequate mixing; freeze–thaw degradation	Vortex thoroughly before each use; use fresh single-use aliquots

Frequently asked questions

What is the best solvent for preparing an Oridonin stock solution?

DMSO (anhydrous, cell-culture grade) is the most widely used solvent for Oridonin stock solutions. A starting concentration of 10 mM in DMSO is a practical choice for most cell-based assays. The DMSO stock should then be diluted into aqueous culture medium immediately before use to keep the final DMSO concentration at or below 0.1 % (v/v).

How should Oridonin (O111381) be stored to maintain stability?

Oridonin powder should be stored at −20 °C in a sealed container, protected from light and moisture. DMSO stock solutions should also be stored at −20 °C in single-use aliquots to avoid repeated freeze–thaw cycles, which can accelerate degradation. Verify stability by HPLC if material has been stored for an extended period.

What vehicle control should be used in Oridonin cell experiments?

Always include a vehicle control containing the same volume of DMSO (without Oridonin) as used in the highest compound concentration well. The final DMSO concentration must be matched across all experimental groups and should not exceed 0.1 % (v/v) to ensure any observed effects are attributable to Oridonin and not to the solvent.

Can Oridonin be dissolved directly in aqueous buffers without DMSO?

Oridonin has limited aqueous solubility and typically requires an organic solvent such as DMSO for initial dissolution. Direct dissolution in PBS or cell-culture medium alone is not recommended as it may result in incomplete dissolution and precipitation, leading to inaccurate dosing. If DMSO must be avoided, consult the literature for alternative solubilization strategies such as cyclodextrin complexation, and validate solubility empirically before use.

Is Oridonin suitable for in vivo animal studies, and does this protocol cover those applications?

This protocol is specifically designed for in vitro cell-based and biochemical assays. In vivo formulation of Oridonin involves additional considerations such as vehicle selection (e.g., PEG-400/saline mixtures or nanoparticle encapsulation), dosing route, and pharmacokinetic profiling, which are beyond the scope of this document. Researchers planning in vivo studies should consult relevant primary literature and institutional animal care guidelines.

References

1. Ikezoe T et al. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 2003. (General reference for Oridonin biological activity — specific volume/page requires verification.)
2. Liu J et al. Oridonin: A review of its pharmacology, pharmacokinetics and toxicity. Cell Prolif. 2021. (Comprehensive review — citation details require verification.)
3. Aladdin Scientific. Certificate of Analysis, Oridonin, SKU O111381. (Lot-specific data; consult current CoA for confirmed purity and physical data.)

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.